German China

Germany: Covid-19

Curevac to Develop Vaccine for Coronavirus

| Editor: Ahlam Rais

Curevac is working on expanding its manufacturing capacities to be able to provide up to billions of doses for outbreak situations like Covid-19.
Gallery: 1 image
Curevac is working on expanding its manufacturing capacities to be able to provide up to billions of doses for outbreak situations like Covid-19. (Source: Deposit Photos)

The German-biopharmaceutical company Curevac is working on developing an mrna-based vaccine that is strong, effective, safe and quick to produce against Covid-19. For this propose, the company is already in touch with numerous organisations and authorities across the globe.

Tübingen/Germany – Curevac, a clinical stage biopharmaceutical company pioneering mrna-based drugs for vaccines and therapeutics, recently confirmed that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.

As a consequence, the company is in contact with Cepi and many other organisations as well as authorities worldwide, however abstains from commenting on speculations and rejects allegations about offers for acquisition of the company or its technology.

Based on its inherent mode of action, Curevac sees mrna as one of the most potent molecules to provide fast and efficient solutions in outbreak scenarios, such like the coronavirus. With in-house expertise of over two decades and the company’s deep scientific understanding, Curevac is leveraging its potent vaccine platform to focus on developing a potent, efficacious and safe and fast to produce vaccine against Covid-19.

Curevac recently announced successful vaccination results in its Rabies programme fully protecting humans with two doses of only 1 microgram (1 millionth of a gram). These results are encouraging when thinking of supplying populations and people worldwide in a pandemic scenario.

The company also has long and strong manufacturing expertise for mrna-based vaccines and therapeutics since 2006. At this time, Curevac is working on expanding its manufacturing capacities to be able to provide up to billions of doses for outbreak situations like Covid-19.

Mariola Fotin-Mleczek, Chief Technology Officer of Curevac, commented: “Nature has invented mechanisms to activate our immune system against infectious diseases. With our unique messenger Rna technology we mimic nature and give our body the information how to fight against the virus. The combination of mrna science, disease understanding, formulation and production expertise make Curevac a unique player to fight against any infectious disease, no matter whether they are seasonal or pandemic.”

Comments are being loaded ....

Leave a comment

The comment is checked by an editor and will be released soon.

  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Contact us via: support.vogel.de/ (ID: 46413187 / Laborpraxis Worldwide)